位置:首页 > 产品库 > (±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane图片
CAS NO:116673-45-1
包装与价格:
包装价格(元)
1mg询价
5mg询价
10mg询价

Cas No.116673-45-1
别名trans-BTP Dioxolane
化学名trans-(±)-2,4-bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
Canonical SMILESCOC1=CC([C@H]2O[C@H](C3=CC(OC)=C(OC)C(OC)=C3)OC2)=CC(OC)=C1OC
分子式C21H26O8
分子量406.4
溶解度≤35mg/ml in ethanol;50mg/ml in DMSO;50mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

(±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane, also known as trans-BTP Dioxolane, is a PAF receptor antagonist [1].

Platelet activating factor (PAF), a phospholipid mediator of inflammation, is secreted by several cell types including arterial endothelial cells, and can activate polymorphonuclear leucocytes and monocytes via specific cell surface receptors. PAF also stimulates the production of active oxygen species by human monocyte - derived macrophages. PAF play important roles in a variety of pathophysiological states including acute allergy, inflammation, asthma, gastrointestinal ulceration, and toxic shock [1].

(±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane is a PAF receptor antagonist. In the rabbit washed platelet assay, (±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane showed good competitive PAF antagonism with Ki value of 0.3 μM, whereas the cis-isomer was much less active.

Reference:
[1].  Corey, E.J.,Chen, C.P., and Parry, M.J. Dual binding modes to the receptor for platelet activating factor (PAF) of anti-PAF trans-2,5-diarylfurans. Tetrahedron Letters 29, 2899-2902 (1988).

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024